Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults

Published on
Journal: Nanoscale
[저자] Pablo Forte-Soto, Muna Albayaty, Dennis Brooks, Rosalinda H Arends, John Tillinghast, Anastasia A Aksyuk, Jerome Bouquet, Cecil Chen, Asfiha Gebre, Robert J Kubiak, Venkatesh Pilla Reddy, Seth Seegobin, Katie Streicher, Alison Templeton, Mark T Esser
[Category] update2024,
PMC URL    Pubmed URL    DOI URL    [DOI] 10.1093/infdis/jiad014    
[Article Type] Major Article
[Source] PMC

A single 300-mg intramuscular AZD7442 dose (150-mg each of tixagevimab/cilgavimab) exhibited an approximate 90-day half-life, was well tolerated in healthy adults (phase 1 study), and could offer protection for ≥6 months against some severe acute respiratory syndrome coronavirus 2 variants.

All Keywords
【저자키워드】 COVID-19, SARS-CoV-2, Safety, monoclonal antibody, pharmacokinetics, Phase 1, Tolerability,